Biotech · Private company · Rockville, MD, US
Rise Therapeutics LLC
Track this companyFree. Adds Rise Therapeutics LLC to your Dealase workspace and tells you when its record changes.
Clinical trials54 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- R-2487Phase 1 · Sjogren's SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- R-2487 DPPhase 1 · Arthritis, RheumatoidClinicalTrials.gov · fetched Nov 12, 2026
- R-3750Phase 1 · Ulcerative Colitis Chronic MildClinicalTrials.gov · fetched Nov 12, 2026
- R-5280Phase 1 · Type 1 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- R-5780Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- R-2487 in Patients With Sjogren's Syndrome (SjD)PHASE1 · NOT_YET_RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT06297213 · fetched Nov 12, 2026
- R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid TumorsPHASE1 · RECRUITING · started Aug 1, 2025ClinicalTrials.gov NCT06398418 · fetched Nov 12, 2026
- R-5280 in Newly Diagnosed Patients With Type 1 DiabetesPHASE1 · COMPLETED · started Dec 5, 2023ClinicalTrials.gov NCT06057454 · fetched Nov 12, 2026
- R-2487 in Patients With Rheumatoid ArthritisPHASE1 · RECRUITING · started Oct 19, 2023ClinicalTrials.gov NCT05961592 · fetched Nov 12, 2026
- R-3750 in Patients With Mild to Moderate Ulcerative ColitisPHASE1 · RECRUITING · started Feb 27, 2023ClinicalTrials.gov NCT05666960 · fetched Nov 12, 2026
NIH awards10
- Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid TumorsFiscal year 2026 · $740.1KNIH RePORTER 1R44CA306440-01A1 · fetched Nov 12, 2026
- A Novel Immunological-Directed Live Biotherapy Product for Treating Crohn's DiseaseFiscal year 2026 · $1MNIH RePORTER 1R44DK146369-01 · fetched Nov 12, 2026
- A Novel Immunological-Directed Probiotic for the Treatment of Sjögren’s SyndromeFiscal year 2026 · $549.8KNIH RePORTER 4UH3DE034134-02 · fetched Nov 12, 2026
- A Novel Immunological-Directed Biotherapy for Treating Rheumatoid ArthritisFiscal year 2026 · $967.7KNIH RePORTER 5R44AG084484-04 · fetched Nov 12, 2026
- A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative ColitisFiscal year 2026 · $811.4KNIH RePORTER 5SB1DK141356-03 · fetched Nov 12, 2026
- A Novel Immunological-Directed Probiotic for the Treatment of Sjögren’s SyndromeFiscal year 2025 · $429.2KNIH RePORTER 1UG3DE034134-01A1 · fetched Nov 12, 2026
- A Novel Immunological-Directed Biotherapy for Treating Rheumatoid ArthritisFiscal year 2025 · $953KNIH RePORTER 5R44AG084484-03 · fetched Nov 12, 2026
- A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple SclerosisFiscal year 2025 · $827.7KNIH RePORTER 5R44AI174844-03 · fetched Nov 12, 2026
- A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative ColitisFiscal year 2025 · $704.6KNIH RePORTER 5SB1DK141356-02 · fetched Nov 12, 2026
- A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative ColitisFiscal year 2024 · $673.4KNIH RePORTER 1SB1DK141356-01 · fetched Nov 12, 2026